Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: A microdialysis study

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 5, 2011, Pages 1055-1062

  Konings, Inge R H M ^a   Sleijfer, Stefan ^a   Mathijssen, Ron H J ^a   De Bruijn, Peter ^a   Ghobadi Moghaddam Helmantel, Inge M ^a   Van Dam, Linda M ^a   Wiemer, Erik A C ^a   Verweij, Jaap ^a   Loos, Walter J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

5 Fluorouracil; Microdialysis; Pharmacokinetics; Target site

Indexed keywords

CARBOPLATIN; EBEFLUORO; FLUOROURACIL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSATE LEVEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; EXTRACELLULAR FLUID; FEMALE; HUMAN; MALE; MICRODIALYSIS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE TUMOR; TISSUE PRESSURE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, MUCOEPIDERMOID; CARCINOMA, NON-SMALL-CELL LUNG; ESOPHAGEAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MELANOMA; MICRODIALYSIS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; SKIN NEOPLASMS; TIME FACTORS;

EID: 79955550102     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1400-3     Document Type: Article

References (36)

1. WC Zamboni S Strychor E Joseph RA Parise MJ Egorin JL Eiseman 2008 Tumor, tissue and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts Cancer Chemother Pharmacol 62 417 426 17957368 10.1007/s00280-007-0620-7 1:CAS:528:DC%2BD1cXnt1eqtbg%3D (Pubitemid 351871800)
2. WC Zamboni S Strychor E Joseph, et al. 2007 Plasma, tumor, and tissue disposition disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts Clin Cancer Res 13 7217 7223 18056203 10.1158/1078-0432.CCR-07-1035 1:CAS:528:DC%2BD2sXhtlyitLjM (Pubitemid 350276909)
3. WC Zamboni PJ Houghton JL Hulstein, et al. 1999 Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines Cancer Chemother Pharmacol 43 269 276 10071976 10.1007/s002800050894 1:CAS:528:DyaK1MXhvFWrsrk%3D (Pubitemid 29075882)
4. M Müller 2002 Science, medicine, and the future: microdialysis Br Med J 324 588 591 10.1136/bmj.324.7337.588
5. O Trédan CM Galmarini K Patel IF Tannock 2007 Drug resistance and the solid tumor microenvironment J Natl Cancer Inst 99 1441 1454 17895480 10.1093/jnci/djm135
6. CA Presant W Wolf V Waluch, et al. 1994 Association of intratumor pharmacokinetics of fluorouracil with clinical response Lancet 343 1184 1187 7909867 10.1016/S0140-6736(94)92399-X 1:STN:280:DyaK2c3jtFylsg%3D%3D (Pubitemid 24147552)
7. CH Heldin K Rubin K Pietras A Östman 2004 High interstitial fluid pressure-an obstacle in cancer therapy Nat Rev Cancer 10 803 813
8. M Müller RM Mader B Steiner, et al. 1997 5-Fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients Cancer Res 57 2598 2601 9205062 (Pubitemid 27283765)
9. RM Mader C Schrolnberger B Rizovski, et al. 2003 Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer Br J Cancer 88 782 787 12618890 10.1038/sj.bjc. 6600809 1:CAS:528:DC%2BD3sXhs1CrsL0%3D (Pubitemid 36411460)
10. I Tegeder L Brautigam M Seegel, et al. 2003 Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer Clin Pharmacol Ther 73 417 426 12732842 10.1016/S0009-9236(03)00008-0 1:CAS:528:DC%2BD3sXjsVGmtL8%3D (Pubitemid 36549826)
11. B Blochl-Daum M Müller V Meisinger, et al. 1996 Measurement of extracellular fluid carboplatin kinetics in melanoma metastases with microdialysis Br J Cancer 73 920 924 8611407 10.1038/bjc.1996.164 1:CAS:528:DyaK28XislKqs7Y%3D (Pubitemid 26110164)
12. C Joukhadar N Klein RM Mader, et al. 2001 Penetration of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide into cutaneous metastases of human malignant melanoma Cancer 92 2190 2196 11596037 10.1002/1097- 0142(20011015)92:8<2190::AID-CNCR1562>3.0.CO;2-2 1:CAS:528: DC%2BD3MXot12ru70%3D (Pubitemid 32973331)
13. PO Ekström A Andersen G Saeter, et al. 1997 Continuous intratumoral microdialysis during high-dose methotrexate therapy in a patient with malignant fibrous histiocytoma of the femur: a case report Cancer Chemother Pharmacol 39 267 272 8996531 (Pubitemid 26414266)
14. M Müller M Brunner R Schmid, et al. 1998 Interstitial methotrexate kinetics in primary breast cancer lesions Cancer Res 58 2982 2985 9679959 (Pubitemid 28335075)
15. IR Konings FK Engels S Sleijfer J Verweij EA Wiemer WJ Loos 2009 Application of prolonged microdialysis sampling in carboplatin-treated cancer patients Cancer Chemother Pharmacol 64 509 516 19096847 10.1007/s00280-008-0898- 0 1:CAS:528:DC%2BD1MXmvV2qsrc%3D
16. BM Wolpin RJ Mayer 2008 Systemic treatment of colorectal cancer Gastroenterology 134 1296 1310 18471507 10.1053/j.gastro.2008.02.098 1:CAS:528:DC%2BD1cXntVWhtL0%3D (Pubitemid 351615376)
17. AD Seidman 2006 Systemic treatment of breast cancer. Two decades of progress Oncology 20 983 990 16986346 (Pubitemid 46940825)
18. Q Pan MA Gorin TN Teknos 2009 Pharmacotherapy of head and neck squamous cell carcinoma Expert Opin Pharmacother 10 2291 2302 19663637 10.1517/14656560903136754 1:CAS:528:DC%2BD1MXhtFCgtb7K
19. T Kubota 2003 5-Fluorouracil and dihydropyrimidine dehydrogenase Int J Clin Oncol 8 127 131 12851835 10.1007/s10147-003-0319-7 1:CAS:528: DC%2BD3sXmt1Wgsbg%3D (Pubitemid 36897281)
20. M Müller R Schmid A Georgopoulos, et al. 1995 Application of microdialysis to clinical pharmacokinetics in humans Clin Pharmacol Ther 57 371 380 7712664 10.1016/0009-9236(95)90205-8
21. JJ Kitzen J Verweij AC Wiemer WJ Loos 2006 The relevance of microdialysis for clinical oncology Curr Clin Pharmacol 1 255 263 18666750 10.2174/157488406778249316 1:CAS:528:DC%2BD28XpvFOnsb8%3D
22. M Czejka J Schuller 1992 [The binding of 5-fluorouracil to serum protein fractions, erythrocytes and ghosts under in vitro conditions] Bindung von 5-Fluorouracil an Serumproteinfraktionen, Erythrozyten und Ghosts unter in vitro Bedingungen Arch Pharm 325 69 71 10.1002/ardp.19923250203 1:CAS:528: DyaK38Xhs1GksLg%3D
23. RK Jain 2001 Delivery of molecular and cellular medicine to solid tumors Adv Drug Deliv Rev 46 149 168 11259838 10.1016/S0169-409X(00)00131-9 1:CAS:528:DC%2BD3MXitVOhsLw%3D
24. LEB Stuhr AV Salnikov VV Iversen G Salvesen K Rubin RK Reed 2006 High-dose, short-term, anti-inflammatory treatment with dexamethasone reduces growth and augments the effects of 5-fluorouracil on dimethyl-α- benzanthracene-induced mammary tumors in rats Scand J Clin Lab Invest 66 477 486 17000555 10.1080/00365510600788332 1:CAS:528:DC%2BD28XhtFyks7%2FM (Pubitemid 44454444)
25. PE Kristjansen Y Boucher RK Jain 1993 Dexamethasone reduces the interstitial fluid pressure in a human colon xenograft Cancer Res 61 6400 6415
26. K Pietras A Östman M Sjöquist, et al. 2001 Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport into tumors Cancer Res 61 2929 2934 11306470 1:CAS:528:DC%2BD3MXivFGqsro%3D (Pubitemid 32691937)
27. K Pietras K Rubin T Sjöblom, et al. 2002 Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy Cancer Res 62 5476 5484 12359756 1:CAS:528:DC%2BD38Xnsl2lsL4%3D
28. AV Salnikov VV Iversen M Koisti, et al. 2003 Lowering of tumour interstitial fluid pressure specifically augments efficacy of chemotherapy FASEB J 17 1756 1758 12958200 1:CAS:528:DC%2BD3sXntlSktrs%3D
29. S Feretti PR Allegrini MM Becquet PMJ McSheehy 2009 Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics Neoplasia 11 874 881
30. G Griffon-Etienne Y Boucher C Brekken HD Suit RK Jain 1999 Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications Cancer Res 59 3776 3782 10446995 1:CAS:528:DyaK1MXltFCns78%3D (Pubitemid 29381886)
31. TPF Gade IM Buchanan MW Motley Y Mazaheri WM Spees JA Koutcher 2009 Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors Clin Cancer Res 15 247 255 19118052 10.1158/1078-0432.CCR-08-0611 1:CAS:528:DC%2BD1MXhs1ersw%3D%3D
32. GJ Peters J Lankelma RM Kok, et al. 1993 Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma Cancer Chemother Pharmacol 31 269 276 8422689 10.1007/BF00685670 1:CAS:528:DyaK3sXhvVaksbo%3D (Pubitemid 23029150)
33. M Stubbs PMJ McSheehy JR Griffiths CL Bashford 2000 Causes and consequences of tumour acidity and implications for treatment Mol Med Today 6 15 19 10637570 10.1016/S1357-4310(99)01615-9 1:CAS:528:DC%2BD3cXms1alsg%3D%3D (Pubitemid 30010232)
34. G Milano AL Chamorey 2002 Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics Chronobiol Int 19 177 189 11962674 10.1081/CBI-120002597 1:CAS:528:DC%2BD38XjsFWjtLo%3D (Pubitemid 34310826)
35. KI Block PB Block SR Fox, et al. 2009 Making circadian cancer therapy practical Integr Cancer Ther 8 371 386 20042412 10.1177/1534735409352028
36. F Lévi C Focan A Karaboué, et al. 2007 Implications of circadian clocks for the rhythmic delivery of cancer therapeutics Adv Drug Deliv Rev 59 1015 10135 17692427 10.1016/j.addr.2006.11.001 (Pubitemid 47542287)